These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24561132)

  • 41. Model-based gene selection shows engrailed 1 is associated with antipsychotic response.
    Webb BT; Sullivan PF; Skelly T; van den Oord EJ
    Pharmacogenet Genomics; 2008 Sep; 18(9):751-9. PubMed ID: 18698228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of genetics on future drug discovery in schizophrenia.
    Matsumoto M; Walton NM; Yamada H; Kondo Y; Marek GJ; Tajinda K
    Expert Opin Drug Discov; 2017 Jul; 12(7):673-686. PubMed ID: 28521526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A systems medicine research approach for studying alcohol addiction.
    Spanagel R; Durstewitz D; Hansson A; Heinz A; Kiefer F; Köhr G; Matthäus F; Nöthen MM; Noori HR; Obermayer K; Rietschel M; Schloss P; Scholz H; Schumann G; Smolka M; Sommer W; Vengeliene V; Walter H; Wurst W; Zimmermann US; ; Stringer S; Smits Y; Derks EM
    Addict Biol; 2013 Nov; 18(6):883-96. PubMed ID: 24283978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.
    de Jong S; Vidler LR; Mokrab Y; Collier DA; Breen G
    J Psychopharmacol; 2016 Aug; 30(8):826-30. PubMed ID: 27302942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The genome as pharmacopeia: association of genetic dose with phenotypic response.
    Wadhawan S; Runz H; Burchard J
    Biochem Pharmacol; 2015 Apr; 94(4):229-40. PubMed ID: 25707983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drug developments in psychosis: Challenges, opportunities and strategies.
    Keshavan MS; Lawler AN; Nasrallah HA; Tandon R
    Prog Neurobiol; 2017 May; 152():3-20. PubMed ID: 27519538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advancing drug discovery for schizophrenia.
    Marder SR; Roth B; Sullivan PF; Scolnick EM; Nestler EJ; Geyer MA; Welnberger DR; Karayiorgou M; Guidotti A; Gingrich J; Akbarian S; Buchanan RW; Lieberman JA; Conn PJ; Haggarty SJ; Law AJ; Campbell B; Krystal JH; Moghaddam B; Sawa A; Caron MG; George SR; Allen JA; Solis M
    Ann N Y Acad Sci; 2011 Oct; 1236():30-43. PubMed ID: 22032400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Special Article: Translational Science Update. Pharmacological Implications of Emerging Schizophrenia Genetics: Can the Bridge From 'Genomics' to 'Therapeutics' be Defined and Traversed?
    Birnbaum R; Weinberger DR
    J Clin Psychopharmacol; 2020; 40(4):323-329. PubMed ID: 32433256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
    Pratt J; Winchester C; Dawson N; Morris B
    Nat Rev Drug Discov; 2012 Jun; 11(7):560-79. PubMed ID: 22722532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.
    Wilson C; Terry AV
    Clin Schizophr Relat Psychoses; 2010 Jul; 4(2):124-37. PubMed ID: 20643635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Schizophrenia risk genes: Implications for future drug development and discovery.
    O'Connell G; Lawrie SM; McIntosh AM; Hall J
    Biochem Pharmacol; 2011 Jun; 81(12):1367-73. PubMed ID: 21093417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current progress in the genetic research of schizophrenia: relevance for drug discovery?
    Rujescu D; Genius J; Benninghoff J; Giegling I
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1614-21. PubMed ID: 22283752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Translating human genetics into novel treatment targets for schizophrenia.
    Schubert CR; Xi HS; Wendland JR; O'Donnell P
    Neuron; 2014 Nov; 84(3):537-41. PubMed ID: 25442931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding translational research in schizophrenia: A novel insight into animal models.
    Malik JA; Yaseen Z; Thotapalli L; Ahmed S; Shaikh MF; Anwar S
    Mol Biol Rep; 2023 Apr; 50(4):3767-3785. PubMed ID: 36692676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of the 6th symposium for the search for the causes of schizophrenia, Sao Paulo, Brazil, 3-6 February 2009.
    Kirkbride JB; Scoriels L
    Eur Arch Psychiatry Clin Neurosci; 2009 Dec; 259(8):505-9. PubMed ID: 19533045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research.
    Mealer RG; Williams SE; Daly MJ; Scolnick EM; Cummings RD; Smoller JW
    Mol Psychiatry; 2020 Dec; 25(12):3129-3139. PubMed ID: 32377000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.
    Lago SG; Bahn S
    NPJ Genom Med; 2022 Mar; 7(1):25. PubMed ID: 35338153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Target validation strategy in designing novel therapeutics for schizophrenia].
    Yoshimizu T; Tajinda K
    Nihon Yakurigaku Zasshi; 2013 Dec; 142(6):265. PubMed ID: 24459740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.